Frontiers in Pharmacology
November 19, 2025
Yan Du, Qing Ma, Xingcui Gao et al.
Introduction Metabolic and gut microbiota (GM) disturbance play a significant role in the complex pathogenesis of substance dependence. Although levo-tetrahydropalmatine (l-THP) demonstrates therapeutic potential in drug addiction, the underlying mechanism remains elusive. Methods The efficacy of l-THP was assessed using a conditioned place preference (CPP) paradigm. In this research, we...
Current gastroenterology reports
November 19, 2025
Wei Zhang, Soo Young Hwang, Jay Luther
1 citation
Alcohol use disorder (AUD) drives alcohol-associated liver disease (ALD), and relapsing after abstinence remains a significant challenge before and after transplantation. This review summarizes evidence for pharmacotherapies in relapse prevention and their integration into ALD care. Naltrexone and acamprosate reduce the relapse in the general AUD population, though data in ALD are limited....
PLoS One
November 14, 2025
correction
Correction: Correction: Effectiveness and satisfaction of mindfulness-based cognitive therapy for children on anxiety, depression, and internet addiction in adolescents: Study protocol for a randomized control trial.
Berkeley Scientific Journal
November 13, 2025
Isabella Mendoza, Alma Razavillar, Aneesa Mustafa et al.
Interview with Dr. Brian Anderson
Journal of Psychoactive Drugs
November 10, 2025
Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes et al.
1 citation
Amid an evolving psychedelic drug policy landscape and limitations of existing substance use disorder (SUD) treatments, a novel addiction recovery paradigm has emerged involving augmentation of 12-Step program engagement with therapeutic psychedelic use. A preliminary qualitative analysis was initiated to describe this movement by examining real-world experiences of participants in remission...
Journal of Neuroscience
November 10, 2025
Sarah N. Magee, Allison C. Sereno, Maria Echeveste Sanchez et al.
Alcohol use disorder (AUD) is a highly prevalent disorder with limited therapeutic options. The central amygdala (CeA) is a critical brain region as dysregulation within the CeA and the corticotropin-releasing factor (CRF) system are associated with AUD pathology. CeA CRF1 receptors regulate alcohol drinking and have served as a therapeutic target in alcohol treatment. One emerging potential...
Journal of Psychoactive Drugs
November 9, 2025
James M Zech, Jérémie Richard, Grant Jones
Psychedelic-assisted interventions are emerging as potential treatments for substance use disorders, including alcohol use disorder (AUD). While recent randomized controlled trials suggest efficacy for certain psychedelics and related compounds in treating AUD, the impact of naturalistic psychedelic use on problematic alcohol consumption remains underexplored. This study examines associations...
JAMA Health Forum
November 7, 2025
Caleigh Propes, Katherine Cheung, Matthew D. Eisenberg et al.
4 citations
This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.
Brain Sciences
November 4, 2025
A. Benjamin Srivastava, Mark S. Gold
The past two decades have seen the reemergence of research investigating the therapeutic potential of psychedelic drugs across neuropsychiatric illnesses. One condition, alcohol use disorder (AUD), is of relevance given the broad public health implications and both limited effectiveness and attrition associated with currently available treatments. While emerging research has suggested that the...
PsyArXiv
November 2, 2025
Sebastian Ehmann, Nathan M. Hager, Paul S. Regier et al.
preprint
Background and AimsThe ongoing opioid epidemic remains a major public health crisis in the United States, with over 100,000 opioid-related deaths annually. Mental health disorders are strongly associated with opioid use disorder (OUD), compounding risks of misuse and overdose. Emerging evidence indicates that psychedelics may be associated with reduced risk of OUD. This study aimed to estimate...
Psychopharmacology
October 31, 2025
Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.
Ayahuasca is a brew containing the psychedelic compound N,N-dimethyltryptamine (DMT) and β-carbolines, traditionally consumed in indigenous rituals. Recent studies suggest its potential to reduce depression and anxiety and as an alternative for treating ethanol and tobacco use disorders. However, research on its impact on cocaine use disorder remains limited. To analyze the rewarding effects of...
Journal of Addictions & Offender Counseling
October 24, 2025
Gina Sugiana Sugara, Salma Rachmawati, Muhammad Muhajirin et al.
This study evaluates the effectiveness of an 8‐week Mindfulness‐Based Stress Reduction (MBSR) intervention in reducing social media addiction among 22 adolescents. The program incorporated techniques such as body scan, sitting meditation, STOP, and RAIN meditation. Results indicated a significant reduction in social media addiction scores ( p < 0.001, d = 1.68) and an increase in mindfulness...
Frontiers in Psychiatry
October 24, 2025
Fares Qeadan, Ashlie McCunn, Benjamin Tingey et al.
Aims: To examine associations between psychedelic use and adverse health outcomes, including overdose, relapse, mental health crises, and hospitalizations, among individuals with substance use disorders (SUD), and to compare these outcomes across different treatment modalities including anesthetics and outpatient SUD services. Design: Retrospective cohort study using propensity score-weighted...
Healthcare
October 23, 2025
Eve E. Keighley, Eid Abo Hamza, Dalia A Bedewy et al.
1 citation
Objectives: This study investigates psychedelic drugs to treat substance use disorder (SUD). Researchers have recently begun conducting clinical trials of psychedelic treatment for SUD. The current meta-analysis investigates the extent of efficacy in alleviating SM behaviours (P) using psychedelic therapy (I), concurrent with determining which psychedelic enables the greatest effect (C) as a...
Open Science Framework
October 20, 2025
Natalia Fernandez‐Vinson, Roger Atkins, Marcus J. Glennon et al.
preprint
This study examines the existence and mechanistic underpinnings of lasting neural, cognitive, and behavioural plasticity in response to N-N-dimethyltryptamine (DMT) in a hazardous drinking population. It combines behavioural, neuroimaging, ecological momentary and qualitative data to gain a holistic understanding of potential mechanisms of therapeutic change following DMT. Primarily, we test...
Preprints.org
October 17, 2025
Jacques Suspène, Sarah Huet, Sabine Berteina‐raboin et al.
preprint
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to prevent relapse. At the same time, psilocybin is increasingly being investigated for the treatment of various substance use disorder. This review aims to evaluate the results of the most recent clinical trials assessing psilocybin as a treatment for...
CNS Drugs
October 16, 2025
Gisèle Pickering, Véronique Morel, Marion Voute
2 citations
Ketamine, an anaesthetic and sedative drug, has emerged as a promising therapeutic option for the management of chronic refractory pain, but is used off-label in this indication and known for its psychomimetic side-effects. The primary objective of this manuscript is to synthesize the current evidence on ketamine efficacy and safety for chronic refractory pain. Furthermore, it aims to identify...
Pharmaceutical Science
October 13, 2025
Berta Fumàs, David Pubill, Raúl López‐arnau et al.
Substance Use Disorder (SUD) is a chronic, relapsing mental health condition characterized by compulsive substance use despite harmful consequences. According to the World Health Organization, in 2021, approximately 39.5 million individuals worldwide suffered from drug use disorders, contributing to an estimated 600,000 deaths annually. Moreover, current pharmacological treatment, such as...
Folia Medica Cracoviensia
October 10, 2025
Angelika Ziaja, Ewa Niedzielska, Krzysztof Ciszkowski et al.
INTRODUCTION: Natural hallucinogens have been known since ancient times and were widely used in religious, shamanic, and folk rituals, as well as in traditional medicine. These compounds originate from plants, animals, and fungi and exhibit considerable diversity. Different groups of substances vary in their mechanisms of action, receptor responses, effects induced, and therapeutic...
Journal of Psychoactive Drugs
October 10, 2025
Mitch Earleywine, Caitlin Holley, Henry A MacConnel et al.
MDMA-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) shows promise, but attitudes and beliefs about this treatment, especially in symptomatic veterans, remain poorly understood. We sought to explore relevant attitudes in veterans receiving healthcare from Veterans Affairs as a step toward designing relevant surveys or psychoeducation materials for future work. We employed a...